3.82
price up icon2.69%   0.10
after-market Handel nachbörslich: 3.74 -0.08 -2.09%
loading
Schlusskurs vom Vortag:
$3.72
Offen:
$3.65
24-Stunden-Volumen:
28,240
Relative Volume:
0.32
Marktkapitalisierung:
$41.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-2.1461
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
+0.53%
1M Leistung:
-11.78%
6M Leistung:
-4.26%
1J Leistung:
-57.70%
1-Tages-Spanne:
Value
$3.58
$3.82
1-Wochen-Bereich:
Value
$3.58
$3.9593
52-Wochen-Spanne:
Value
$2.79
$11.99

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Firmenname
Lantern Pharma Inc
Name
Telefon
972-277-1136
Name
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Mitarbeiter
21
Name
Twitter
@lanternpharma
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
LTRN's Discussions on Twitter

Vergleichen Sie LTRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LTRN
Lantern Pharma Inc
3.82 41.20M 0 -19.09M -17.24M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.20 129.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
658.48 71.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.02 37.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
283.34 36.68B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
251.98 27.10B 3.81B -644.79M -669.77M -6.24

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-10-07 Eingeleitet H.C. Wainwright Buy

Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten

pulisher
Mar 20, 2025

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace

Mar 20, 2025
pulisher
Mar 20, 2025

Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - StockTitan

Mar 20, 2025
pulisher
Mar 10, 2025

LTRN: M&A Illuminates GBM Value - Yahoo Finance

Mar 10, 2025
pulisher
Mar 10, 2025

Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World

Mar 07, 2025
pulisher
Feb 20, 2025

Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey

Feb 20, 2025
pulisher
Feb 19, 2025

Lantern Pharma advances AI-driven drug development with patent - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria

Feb 19, 2025
pulisher
Feb 19, 2025

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire

Feb 19, 2025
pulisher
Feb 04, 2025

Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World

Feb 04, 2025
pulisher
Jan 28, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World

Jan 28, 2025
pulisher
Jan 27, 2025

Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance

Jan 27, 2025
pulisher
Jan 27, 2025

Top 10 AI Stocks Dominating Wall Street - Insider Monkey

Jan 27, 2025
pulisher
Jan 27, 2025

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace

Jan 27, 2025
pulisher
Jan 26, 2025

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 21, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jan 21, 2025
pulisher
Jan 17, 2025

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey

Jan 17, 2025
pulisher
Jan 10, 2025

Lantern Pharma Extends CSO’s Employment Agreement - TipRanks

Jan 10, 2025
pulisher
Jan 04, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World

Jan 04, 2025
pulisher
Jan 02, 2025

Oncology Drugs Fast-Tracked by the FDA in December 2024 - Oncology News Central

Jan 02, 2025
pulisher
Dec 22, 2024

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance

Dec 22, 2024
pulisher
Dec 10, 2024

AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey

Dec 10, 2024
pulisher
Dec 09, 2024

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance

Dec 09, 2024
pulisher
Dec 09, 2024

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire

Dec 09, 2024
pulisher
Dec 07, 2024

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance

Dec 07, 2024
pulisher
Dec 06, 2024

15 AI News Updates That Broke The Internet - Insider Monkey

Dec 06, 2024
pulisher
Dec 03, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Dec 03, 2024
pulisher
Dec 03, 2024

Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com

Dec 03, 2024
pulisher
Dec 03, 2024

LP-184 gains FDA fast track for triple negative breast cancer - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune

Dec 03, 2024
pulisher
Nov 26, 2024

Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 26, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire

Nov 26, 2024
pulisher
Nov 21, 2024

10 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Nov 21, 2024
pulisher
Nov 20, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 14, 2024

32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.

Nov 14, 2024
pulisher
Nov 13, 2024

III: TechBio News Day 👾 - substack.com

Nov 13, 2024
pulisher
Nov 12, 2024

LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India

Nov 11, 2024
pulisher
Nov 09, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada

Nov 09, 2024
pulisher
Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance

Nov 08, 2024

Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$312.99
price down icon 0.19%
$79.92
price up icon 1.46%
$19.75
price up icon 1.59%
$33.70
price up icon 0.60%
$95.38
price down icon 0.88%
biotechnology ONC
$251.98
price down icon 4.04%
Kapitalisierung:     |  Volumen (24h):